Atrial Fibrillation (AF) is the most common sustained arrhythmia, and its incidence and prevalence are increasing both in the United States and globally [1,2]. The prevalence of AF in the United States was estimated to be 5.2 million in 2010, with an expected rise to 12.1 million by 2030 [1]. Corresponding estimates for the incidence of AF in the U.S. were 1.2 million cases in 2010, projected to increase to 2.6 million cases by 2030 [1]. The rate of AF diagnosis varies according to factors such as education, income [3], clinical presentation [4,5], and genetic predisposition [4]. AF is associated with a 1.5- to 2-fold increased risk of mortality [6,7]; studies suggest that this risk may be higher in women than in men [6]. Meta-analyses have also shown that AF is linked to an increased risk of several adverse outcomes, including a 2.4-fold risk of stroke [7], a 1.5-fold risk of cognitive impairment or dementia [8], a 1.5-fold risk of Myocardial Infarction (MI) [9], a 2-fold risk of sudden cardiac death [10], a 5-fold risk of Heart Failure (HF) [7], a 1.6-fold risk of Chronic Kidney Disease (CKD) [7], and a 1.3-fold risk of Peripheral Artery Disease (PAD) [7].